Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

First Posted Date
2021-12-03
Last Posted Date
2021-12-03
Lead Sponsor
Huazhong University of Science and Technology
Target Recruit Count
30
Registration Number
NCT05142865
Locations
🇨🇳

Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

First Posted Date
2021-11-10
Last Posted Date
2024-05-31
Lead Sponsor
Akeso
Target Recruit Count
35
Registration Number
NCT05116007
Locations
🇨🇳

Shun Lu, Shanghai, Shanghai, China

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

First Posted Date
2021-11-03
Last Posted Date
2024-07-09
Lead Sponsor
Theodore S. Johnson
Target Recruit Count
37
Registration Number
NCT05106296
Locations
🇺🇸

Augusta University, Georgia Cancer Center, Augusta, Georgia, United States

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

First Posted Date
2021-10-25
Last Posted Date
2024-10-29
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
690
Registration Number
NCT05091567
Locations
🇺🇸

Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States

🇺🇸

Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States

🇺🇸

SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States

and more 103 locations

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

First Posted Date
2021-10-05
Last Posted Date
2024-05-14
Lead Sponsor
University of Chicago
Target Recruit Count
49
Registration Number
NCT05068232
Locations
🇺🇸

University of Chicago Medicine, Chicago, Illinois, United States

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

First Posted Date
2021-09-28
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
189
Registration Number
NCT05058651
Locations
🇺🇸

Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

🇺🇸

Kaiser Permanente-Anaheim, Anaheim, California, United States

and more 201 locations

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

First Posted Date
2021-09-20
Last Posted Date
2021-09-20
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
100
Registration Number
NCT05049473
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospital del Mar, Barcelona, Spain

🇪🇸

ICO-Hospital Duran i Reynals, Bellvitge, Spain

and more 26 locations

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

First Posted Date
2021-08-30
Last Posted Date
2023-07-19
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
60
Registration Number
NCT05026593
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

First Posted Date
2021-08-25
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT05019716
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 2 locations

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

First Posted Date
2021-08-17
Last Posted Date
2024-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
146
Registration Number
NCT05008224
Locations
🇺🇸

Stanford Cancer Center ( Site 0023), Palo Alto, California, United States

🇺🇸

Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States

🇺🇸

Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States

and more 45 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy